In this study we evaluated the day to day prostate displacement during radiation therapy by using implanted radiopaque fiducials and daily image guided position verification.
The data of 10 patients that received radiation therapy to the prostate were analyzed. Three fiducial markers were implanted in the prostate before treatment initiation for everyday verification of the target's position. Daily X ray images (kilovolt/KV films) of the pelvis were acquired for verification and were matched with baseline images produced during treatment preparation using bony structures and fiducials as landmarks. We calculated the mean difference between the two methods and the prostate displacement derived from these measurements.
A total of 208 KV films were obtained. Our results showed a non-uniform prostate motion, with most of the displacements observed in the caudal direction followed by anterior, posterior, cranial, right and left. The mean target motion in each of the above directions was 3.5 mm, 3.5 mm, 3.3 mm, 3.9 mm, 2 mm and 2.4 mm. Based on the cumulative frequency of the target's displacement, a margin of 8 mm, 7mm, 5 mm, 4 mm, 9 mm and 7 mm in the anterior, posterior, left, right, cranial and caudal direction respectively would account for 95% of prostate's motion, provided that every day KV image guidance is performed.
A non-isotopic margin of 8 mm, 7mm, 5 mm, 4 mm, 9 mm and 7 mm around the prostate can be considered safe for treatment delivery.
A non-isotopic margin of 8 mm, 7mm, 5 mm, 4 mm, 9 mm and 7 mm around the prostate can be considered safe for treatment delivery.To evaluate the efficacy and safety of radiofrequency ablation (RFA) and transcatheter arterial chemoembolization (TACE) combined with postoperative cytokine-induced killer (CIK) cell immunotherapy in the treatment of primary hepatocellular carcinoma (HCC).
The clinical data of 116 patients with primary HCC treated in our hospital from March 2016 to January 2018 were collected. 58 patients were treated with RFA+TACE (RFA+TACE group), and the other 58 patients underwent RFA+TACE+CIK cell immunotherapy (RFA+TACE+CIK group). Before and after treatment, the proportions of cluster of differentiation 3+ (CD3+), CD3+CD4+, and CD3+CD8+ T cells, regulatory T cells (Tregs) and natural killer (NK) cells and the CD4+/CD8+ ratio were detected via flow cytometry, and the levels of serum interferon-γ (IFN-γ), interleukin-2 (IL-2) and IL-6 were detected via enzyme-linked immunosorbent assay (ELISA). The incidence of adverse reactions and the quality of life score of patients after treatment were compared between the two .1±5.6) months and (37.8±4.8) months, and the 5-year OS rate was 29.3% (17/58) and 13.8% (8/58), respectively, in RFA+TACE+CIK group and RFA+TACE group. The results of log-rank test showed that the OS in RFA+TACE+CIK group was significantly superior to that in RFA+TACE group.
RFA and TACE combined with postoperative autologous CIK cell reinfusion have significant efficacy in the treatment of primary HCC, which can enhance the immune function, improve the postoperative quality of life and raise the survival rate of patients, with tolerable adverse reactions.
RFA and TACE combined with postoperative autologous CIK cell reinfusion have significant efficacy in the treatment of primary HCC, which can enhance the immune function, improve the postoperative quality of life and raise the survival rate of patients, with tolerable adverse reactions.Ovarian cancer (OC) is a serious threat to women's life. OC is insidious and lacks early diagnosis and effective treatment. https://www.selleckchem.com/products/mrtx849.html Therefore, it is vital to look for new therapeutic targets and biomarkers.
MicroRNA-877 (miR-877) expression level in OC was accessed via quantitative real-time polymerase chain reaction (qRT-PCR). Transwell assay, Matrigel assay and wound healing assay were used to analyze the ability of miR-877 on cell migration and invasion. Luciferase reporter assay was employed for verification the target of miR-877. Western blotting was taken in for the determination of the expression level of FOXM1.
MiR-877 had low expression level in OC tissues and cell lines. MiR-877 over-expression induced inhibition of cell migration and invasion. FOXM1 was a direct target of miR-877. MiR-877 restrained cell migration and invasion by negatively regulating FOXM1 expression in OC.
Our research elucidated that miR-877 played a role of tumor suppressor in OC by negatively regulating FOXM1 which may bring a novel insight into new molecular therapeutic targets and biomarkers for OC.
Our research elucidated that miR-877 played a role of tumor suppressor in OC by negatively regulating FOXM1 which may bring a novel insight into new molecular therapeutic targets and biomarkers for OC.This study initially explored the expression of GDF-15 in gallbladder carcinoma and its clinical significance, and analyzed the correlation between the expression of GDF-15 and the clinicopathological features as well as the prognosis of patients with gallbladder carcinoma.
Enzyme-linked immunosorbent assay (ELISA) was used to determine the expression of GDF-15 in the serum of 42 patients with gallbladder cancer. The control group included 24 patients with cholecystitis and 20 healthy volunteers. The immunohistochemical method (IHC) was used to detect the expression of GDF-15 in 42 cases of gallbladder tumor tissue and 35 cases of adjacent non-tumor gallbladder tissue specimens.
The results of ELISA showed that the concentration of GDF-15 in serum was considerably higher in gallbladder cancer patients than that in gallbladder benign lesions and healthy volunteers (p=0.006, p&lt;0.001). In the group of patients with gallbladder cancer, the consistence of GDF-15 in patients with lymph node metastasis was significantly higher than that of patients without lymph node metastasis (p&lt;0.001). Immunohistochemical staining showed that the expression of GDF-15 in gallbladder carcinoma was markedly higher than that in non-tumor gallbladder tissues (p=0.003), and the high expression of GDF-15 was significantly correlated with the differentiation grade of gallbladder carcinoma and tumor TNM stage (p=0.005, p=0.002).
GDF-15 is related to the occurrence and development of gallbladder cancer. GDF-15 in serum can be used as a potential marker for the diagnosis of gallbladder cancer and can be used to predict the lymph node metastasis of gallbladder cancer.
GDF-15 is related to the occurrence and development of gallbladder cancer. GDF-15 in serum can be used as a potential marker for the diagnosis of gallbladder cancer and can be used to predict the lymph node metastasis of gallbladder cancer.